DNTH Stock Summary and Trading Ideas (Dianthus Therapeutics | NASDAQ:DNTH)

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.

As of October 21, 2026, DNTH stock price declined to $78.10 with 476,428 million shares trading.

DNTH has a beta of -0.05, meaning it tends to be less sensitive to market movements. DNTH has a correlation of 0.00 to the broad based SPY ETF.

DNTH has a market cap of $4.37 billion. This is considered a Mid Cap stock.

Last quarter Dianthus Therapeutics reported $761,000 in Revenue and -$.90 earnings per share. This beat revenue expectation by $468,000 and exceeded earnings estimates by $.01.

In the last 3 years, DNTH traded as high as $117.88 and as low as $6.58.

The top ETF exchange traded funds that DNTH belongs to (by Net Assets): VTI, XBI, IWM, VXF, VB.

DNTH has outperformed the market in the last year with a return of +116.9%, while the SPY ETF gained +16.3%. However, in the most recent history, DNTH shares have underperformed the stock market with its stock returning -22.7% in the last 3 month period and -8.5% for the last 2 week period, while SPY has returned +4.4% and -0.8%, respectively.

DNTH support price is $76.01 and resistance is $81.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.